patient_id stringlengths 12 12 | record_id stringlengths 11 11 | cancer_type stringclasses 1
value | histology stringclasses 3
values | stage_at_diagnosis stringclasses 3
values | driver_mutation stringclasses 7
values | pd_l1_tps_percent int64 5 41 | tmb_mutations_per_mb float64 1.5 25 | age_at_diagnosis int64 38 90 | sex stringclasses 2
values | ecog_performance_status int64 0 4 | smoking_pack_years int64 0 111 | primary_tumor_size_cm float64 2 10 | metastatic_sites_count int64 0 11 | first_line_regimen stringclasses 6
values | overall_survival_months float64 4 83 | censored bool 2
classes | msi_status stringclasses 2
values | record_generation_timestamp stringdate 2026-03-15 05:35:56 2026-03-15 05:36:02 | synthetic_source stringclasses 1
value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ANODE_102180 | REC_0016701 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 23 | 17.6 | 52 | female | 0 | 11 | 5.5 | 1 | sotorasib 960 mg daily | 8.5 | false | MSS | 2026-03-15T05:36:01.853231+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_726163 | REC_0016702 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None (PD-L1 high) | 29 | 5.5 | 68 | female | 1 | 77 | 7 | 2 | pembrolizumab 200 mg q3w | 13.2 | true | MSS | 2026-03-15T05:36:01.853598+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_396026 | REC_0016703 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 32 | 15.4 | 69 | female | 0 | 9 | 7 | 3 | osimertinib 80 mg daily | 11.5 | false | MSI-H | 2026-03-15T05:36:01.853977+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_908024 | REC_0016704 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 32 | 11.8 | 77 | female | 1 | 15 | 3.1 | 2 | osimertinib 80 mg daily | 17.9 | true | MSI-H | 2026-03-15T05:36:01.854362+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_372534 | REC_0016705 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 24 | 9.4 | 72 | female | 2 | 10 | 6.2 | 5 | alectinib 600 mg BID | 7.5 | false | MSS | 2026-03-15T05:36:01.854753+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_423396 | REC_0016706 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 22 | 6.1 | 76 | female | 1 | 39 | 5.5 | 9 | pembrolizumab 200 mg q3w | 7.5 | true | MSS | 2026-03-15T05:36:01.855319+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_520972 | REC_0016707 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 27 | 9.1 | 63 | female | 1 | 12 | 7.2 | 5 | entrectinib 600 mg daily | 9.9 | false | MSS | 2026-03-15T05:36:01.855754+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_709152 | REC_0016708 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 36 | 13.3 | 68 | female | 1 | 23 | 5.2 | 6 | entrectinib 600 mg daily | 12.2 | true | MSS | 2026-03-15T05:36:01.856210+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_763219 | REC_0016709 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 17 | 8.9 | 67 | female | 0 | 10 | 4 | 1 | alectinib 600 mg BID | 7.3 | true | MSS | 2026-03-15T05:36:01.856629+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_701384 | REC_0016710 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 25 | 3 | 66 | female | 0 | 15 | 4.2 | 4 | pembrolizumab 200 mg q3w | 16.2 | false | MSS | 2026-03-15T05:36:01.857028+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_631608 | REC_0016711 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 18 | 11.1 | 62 | male | 0 | 24 | 7.4 | 4 | osimertinib 80 mg daily | 6.5 | true | MSS | 2026-03-15T05:36:01.857399+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_139216 | REC_0016712 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 28 | 12.9 | 62 | male | 1 | 17 | 5.8 | 1 | alectinib 600 mg BID | 12.6 | false | MSI-H | 2026-03-15T05:36:01.857724+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_219678 | REC_0016713 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 25 | 6.1 | 67 | male | 0 | 21 | 5.9 | 1 | sotorasib 960 mg daily | 15.4 | true | MSS | 2026-03-15T05:36:01.858059+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_369494 | REC_0016714 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 25 | 4.6 | 69 | female | 1 | 9 | 6.7 | 5 | pembrolizumab 200 mg q3w | 4 | true | MSS | 2026-03-15T05:36:01.858405+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_626122 | REC_0016715 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 27 | 5.1 | 64 | male | 1 | 72 | 6.9 | 3 | carboplatin + paclitaxel + pembrolizumab | 25.3 | false | MSS | 2026-03-15T05:36:01.858768+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_388022 | REC_0016716 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 25 | 4.9 | 70 | female | 2 | 40 | 5.7 | 3 | carboplatin + paclitaxel + pembrolizumab | 7.4 | true | MSS | 2026-03-15T05:36:01.859130+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_843580 | REC_0016717 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 26 | 9.2 | 57 | female | 0 | 6 | 4.6 | 4 | sotorasib 960 mg daily | 11.5 | true | MSS | 2026-03-15T05:36:01.859497+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_264300 | REC_0016718 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 32 | 9.2 | 55 | male | 1 | 9 | 3.8 | 6 | sotorasib 960 mg daily | 9.3 | true | MSS | 2026-03-15T05:36:01.859929+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_237329 | REC_0016719 | Non-small cell lung cancer | Adenocarcinoma | III | EGFR L858R | 24 | 13.1 | 74 | female | 1 | 12 | 4.5 | 0 | osimertinib 80 mg daily | 16.5 | false | MSS | 2026-03-15T05:36:01.860606+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_790351 | REC_0016720 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 18 | 10.7 | 73 | male | 1 | 19 | 4.9 | 2 | osimertinib 80 mg daily | 22.5 | true | MSI-H | 2026-03-15T05:36:01.861034+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_862321 | REC_0016721 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 22 | 12 | 69 | female | 1 | 19 | 7 | 8 | pembrolizumab 200 mg q3w | 12.2 | true | MSI-H | 2026-03-15T05:36:01.861472+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_961229 | REC_0016722 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 30 | 8.7 | 52 | male | 0 | 55 | 3.5 | 4 | carboplatin + paclitaxel + pembrolizumab | 13.3 | true | MSS | 2026-03-15T05:36:01.861872+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_271126 | REC_0016723 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 27 | 8.8 | 71 | male | 2 | 19 | 6.6 | 8 | osimertinib 80 mg daily | 12 | true | MSS | 2026-03-15T05:36:01.862237+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_549084 | REC_0016724 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 16 | 11.4 | 67 | male | 1 | 9 | 3.4 | 6 | sotorasib 960 mg daily | 9.2 | false | MSS | 2026-03-15T05:36:01.862593+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_844690 | REC_0016725 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 21 | 10.5 | 84 | female | 2 | 9 | 5.3 | 5 | alectinib 600 mg BID | 12.8 | false | MSS | 2026-03-15T05:36:01.862954+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_658911 | REC_0016726 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 23 | 9.6 | 66 | female | 1 | 16 | 4.2 | 6 | osimertinib 80 mg daily | 4.7 | false | MSS | 2026-03-15T05:36:01.863297+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_194800 | REC_0016727 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 24 | 13.7 | 69 | female | 1 | 17 | 6.3 | 5 | osimertinib 80 mg daily | 9.2 | true | MSS | 2026-03-15T05:36:01.863626+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_875918 | REC_0016728 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 22 | 11.6 | 62 | female | 1 | 18 | 6.3 | 2 | sotorasib 960 mg daily | 8.9 | true | MSI-H | 2026-03-15T05:36:01.863956+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_651040 | REC_0016729 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 24 | 5 | 69 | male | 0 | 29 | 4.4 | 6 | pembrolizumab 200 mg q3w | 15.4 | false | MSS | 2026-03-15T05:36:01.864408+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_160068 | REC_0016730 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 19 | 13.8 | 69 | female | 1 | 14 | 5.4 | 1 | alectinib 600 mg BID | 22.6 | true | MSS | 2026-03-15T05:36:01.864786+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_860046 | REC_0016731 | Non-small cell lung cancer | Adenocarcinoma | III | ALK fusion | 31 | 16.4 | 64 | male | 1 | 19 | 4.5 | 0 | alectinib 600 mg BID | 39.4 | false | MSI-H | 2026-03-15T05:36:01.865168+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_798510 | REC_0016732 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 30 | 11 | 59 | female | 1 | 17 | 7.3 | 5 | alectinib 600 mg BID | 14 | false | MSI-H | 2026-03-15T05:36:01.865727+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_605503 | REC_0016733 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 30 | 11 | 55 | male | 1 | 18 | 2.6 | 4 | osimertinib 80 mg daily | 15.6 | false | MSS | 2026-03-15T05:36:01.866154+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_463369 | REC_0016734 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 17 | 5.1 | 90 | female | 2 | 40 | 5.7 | 5 | pembrolizumab 200 mg q3w | 4 | false | MSS | 2026-03-15T05:36:01.866567+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_601585 | REC_0016735 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 23 | 12.7 | 65 | male | 0 | 16 | 4.7 | 5 | alectinib 600 mg BID | 12.6 | true | MSI-H | 2026-03-15T05:36:01.866952+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_730197 | REC_0016736 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 19 | 6 | 67 | female | 1 | 21 | 4.5 | 6 | carboplatin + paclitaxel + pembrolizumab | 13.1 | true | MSS | 2026-03-15T05:36:01.867337+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_488671 | REC_0016737 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 29 | 6 | 64 | female | 0 | 6 | 6.5 | 1 | carboplatin + paclitaxel + pembrolizumab | 16.9 | false | MSS | 2026-03-15T05:36:01.867680+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_913326 | REC_0016738 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 20 | 11.8 | 78 | female | 2 | 25 | 5.4 | 4 | alectinib 600 mg BID | 14.1 | false | MSS | 2026-03-15T05:36:01.868010+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_652303 | REC_0016739 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 19 | 8.3 | 61 | female | 1 | 23 | 4.4 | 5 | alectinib 600 mg BID | 5 | true | MSS | 2026-03-15T05:36:01.868464+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_198711 | REC_0016740 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 26 | 13.2 | 64 | male | 0 | 3 | 7.2 | 5 | sotorasib 960 mg daily | 17.2 | false | MSI-H | 2026-03-15T05:36:01.868841+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_612502 | REC_0016741 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 24 | 9.1 | 65 | female | 1 | 16 | 5.4 | 1 | sotorasib 960 mg daily | 17.7 | true | MSS | 2026-03-15T05:36:01.869220+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_487758 | REC_0016742 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 25 | 6.4 | 76 | female | 2 | 34 | 4.2 | 2 | carboplatin + paclitaxel + pembrolizumab | 15.5 | false | MSS | 2026-03-15T05:36:01.869551+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_600679 | REC_0016743 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 25 | 17 | 70 | female | 2 | 16 | 7.4 | 2 | osimertinib 80 mg daily | 17.2 | false | MSS | 2026-03-15T05:36:01.869916+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_923160 | REC_0016744 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 31 | 15.7 | 64 | female | 0 | 11 | 4.8 | 5 | alectinib 600 mg BID | 16.7 | true | MSI-H | 2026-03-15T05:36:01.870288+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_577926 | REC_0016745 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 27 | 5.1 | 63 | male | 1 | 38 | 3.7 | 8 | carboplatin + paclitaxel + pembrolizumab | 9.6 | false | MSS | 2026-03-15T05:36:01.870842+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_490649 | REC_0016746 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 25 | 12.4 | 69 | female | 1 | 12 | 7.7 | 7 | entrectinib 600 mg daily | 12.1 | false | MSS | 2026-03-15T05:36:01.871273+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_787877 | REC_0016747 | Non-small cell lung cancer | Adenocarcinoma | III | KRAS G12C | 23 | 10.4 | 75 | female | 2 | 17 | 6.1 | 0 | sotorasib 960 mg daily | 36.4 | false | MSI-H | 2026-03-15T05:36:01.871702+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_224030 | REC_0016748 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 25 | 3.9 | 56 | female | 0 | 43 | 5.7 | 5 | carboplatin + paclitaxel + pembrolizumab | 13.9 | true | MSS | 2026-03-15T05:36:01.872161+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_438773 | REC_0016749 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 29 | 17.6 | 59 | female | 0 | 23 | 5.8 | 4 | alectinib 600 mg BID | 7.5 | true | MSI-H | 2026-03-15T05:36:01.873176+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_121928 | REC_0016750 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 20 | 4.8 | 50 | male | 0 | 51 | 5.9 | 1 | carboplatin + paclitaxel + pembrolizumab | 25 | true | MSS | 2026-03-15T05:36:01.873648+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_572231 | REC_0016751 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 30 | 6.7 | 75 | female | 2 | 28 | 6.4 | 4 | carboplatin + paclitaxel + pembrolizumab | 13.4 | false | MSS | 2026-03-15T05:36:01.874061+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_274542 | REC_0016752 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 29 | 7.2 | 75 | female | 2 | 2 | 4.6 | 1 | entrectinib 600 mg daily | 23.7 | true | MSS | 2026-03-15T05:36:01.874455+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_281799 | REC_0016753 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 22 | 19 | 74 | female | 1 | 21 | 8.5 | 3 | osimertinib 80 mg daily | 23.1 | false | MSI-H | 2026-03-15T05:36:01.874882+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_174248 | REC_0016754 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 22 | 10.3 | 61 | female | 0 | 7 | 6.4 | 3 | sotorasib 960 mg daily | 8.9 | true | MSI-H | 2026-03-15T05:36:01.875280+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_124694 | REC_0016755 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 29 | 13 | 71 | female | 2 | 0 | 6.3 | 2 | entrectinib 600 mg daily | 21.5 | false | MSI-H | 2026-03-15T05:36:01.875667+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_470847 | REC_0016756 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 19 | 17.1 | 77 | female | 2 | 15 | 4 | 6 | osimertinib 80 mg daily | 8.4 | false | MSI-H | 2026-03-15T05:36:01.876044+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_611105 | REC_0016757 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 22 | 4.6 | 68 | female | 1 | 5 | 6.8 | 1 | osimertinib 80 mg daily | 23.9 | true | MSS | 2026-03-15T05:36:01.876468+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_848574 | REC_0016758 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 21 | 6.4 | 70 | female | 2 | 12 | 6.7 | 2 | osimertinib 80 mg daily | 10.1 | false | MSS | 2026-03-15T05:36:01.877109+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_723951 | REC_0016759 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 25 | 7.7 | 75 | female | 2 | 10 | 6.1 | 1 | sotorasib 960 mg daily | 18.1 | true | MSS | 2026-03-15T05:36:01.877540+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_238150 | REC_0016760 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 31 | 13.8 | 68 | female | 1 | 18 | 5 | 5 | osimertinib 80 mg daily | 14.4 | false | MSI-H | 2026-03-15T05:36:01.877875+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_774031 | REC_0016761 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 32 | 10.8 | 66 | female | 0 | 13 | 4.5 | 8 | sotorasib 960 mg daily | 7.3 | false | MSI-H | 2026-03-15T05:36:01.878209+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_673779 | REC_0016762 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 28 | 2.1 | 68 | female | 1 | 17 | 2.1 | 2 | alectinib 600 mg BID | 17.2 | false | MSS | 2026-03-15T05:36:01.878528+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_798575 | REC_0016763 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 28 | 7.3 | 67 | female | 1 | 15 | 6.5 | 2 | alectinib 600 mg BID | 10.8 | false | MSS | 2026-03-15T05:36:01.878858+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_807651 | REC_0016764 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 29 | 5.2 | 69 | male | 1 | 15 | 6.1 | 9 | pembrolizumab 200 mg q3w | 9.6 | false | MSS | 2026-03-15T05:36:01.879200+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_174094 | REC_0016765 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 22 | 3.7 | 57 | male | 1 | 8 | 6.7 | 5 | pembrolizumab 200 mg q3w | 4 | false | MSS | 2026-03-15T05:36:01.879544+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_197138 | REC_0016766 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 16 | 7.3 | 78 | female | 2 | 56 | 5.4 | 7 | carboplatin + paclitaxel + pembrolizumab | 7.7 | false | MSS | 2026-03-15T05:36:01.879895+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_945988 | REC_0016767 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 21 | 17.4 | 69 | female | 0 | 21 | 5.9 | 1 | osimertinib 80 mg daily | 21.5 | false | MSS | 2026-03-15T05:36:01.880309+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_816036 | REC_0016768 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 22 | 19.4 | 72 | female | 2 | 9 | 7.2 | 5 | entrectinib 600 mg daily | 15.5 | true | MSI-H | 2026-03-15T05:36:01.880733+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_988046 | REC_0016769 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 23 | 19.3 | 76 | female | 1 | 0 | 6 | 5 | osimertinib 80 mg daily | 9.8 | false | MSS | 2026-03-15T05:36:01.881154+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_641424 | REC_0016770 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 27 | 7.8 | 70 | female | 1 | 20 | 5.2 | 5 | osimertinib 80 mg daily | 9.1 | true | MSS | 2026-03-15T05:36:01.881550+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_569159 | REC_0016771 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 22 | 2.3 | 76 | male | 2 | 47 | 3.6 | 6 | carboplatin + paclitaxel + pembrolizumab | 10.3 | false | MSS | 2026-03-15T05:36:01.882153+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_850668 | REC_0016772 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 28 | 14.8 | 65 | male | 1 | 6 | 8.5 | 2 | osimertinib 80 mg daily | 28.7 | false | MSI-H | 2026-03-15T05:36:01.882629+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_607735 | REC_0016773 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 26 | 16.8 | 74 | female | 2 | 20 | 6.3 | 7 | alectinib 600 mg BID | 7.1 | true | MSI-H | 2026-03-15T05:36:01.883046+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_650464 | REC_0016774 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 21 | 9.7 | 74 | male | 2 | 20 | 4.7 | 6 | alectinib 600 mg BID | 4 | true | MSS | 2026-03-15T05:36:01.883429+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_775356 | REC_0016775 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 27 | 18.7 | 60 | female | 0 | 16 | 6 | 7 | osimertinib 80 mg daily | 16.4 | true | MSI-H | 2026-03-15T05:36:01.883830+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_889060 | REC_0016776 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 29 | 7.7 | 47 | female | 0 | 19 | 7.4 | 5 | sotorasib 960 mg daily | 13.7 | true | MSS | 2026-03-15T05:36:01.884346+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_239597 | REC_0016777 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 22 | 8.3 | 74 | female | 2 | 23 | 5.9 | 5 | entrectinib 600 mg daily | 15.3 | false | MSS | 2026-03-15T05:36:01.884746+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_895630 | REC_0016778 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 26 | 5.2 | 61 | male | 0 | 67 | 5.7 | 4 | carboplatin + paclitaxel + pembrolizumab | 9.6 | true | MSS | 2026-03-15T05:36:01.885163+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_507408 | REC_0016779 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 22 | 9 | 57 | male | 0 | 15 | 5 | 1 | alectinib 600 mg BID | 13.9 | false | MSS | 2026-03-15T05:36:01.885576+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_555403 | REC_0016780 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 23 | 15.7 | 67 | female | 0 | 12 | 4.9 | 1 | osimertinib 80 mg daily | 7.2 | true | MSS | 2026-03-15T05:36:01.885963+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_377553 | REC_0016781 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 22 | 10.5 | 74 | female | 2 | 9 | 7.6 | 10 | osimertinib 80 mg daily | 13.9 | false | MSS | 2026-03-15T05:36:01.886382+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_344425 | REC_0016782 | Non-small cell lung cancer | Adenocarcinoma | III | KRAS G12C | 17 | 6.8 | 60 | female | 1 | 14 | 5.3 | 0 | sotorasib 960 mg daily | 61.7 | true | MSS | 2026-03-15T05:36:01.886779+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_843550 | REC_0016783 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 28 | 13.2 | 78 | female | 1 | 23 | 5.3 | 8 | alectinib 600 mg BID | 6.7 | false | MSS | 2026-03-15T05:36:01.887193+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_535066 | REC_0016784 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 25 | 14.9 | 71 | female | 2 | 18 | 7.1 | 2 | osimertinib 80 mg daily | 18.9 | false | MSI-H | 2026-03-15T05:36:01.887874+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_302509 | REC_0016785 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 24 | 18.8 | 71 | male | 1 | 4 | 4.2 | 5 | sotorasib 960 mg daily | 10.4 | false | MSI-H | 2026-03-15T05:36:01.888425+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_534123 | REC_0016786 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 18 | 6.9 | 69 | female | 0 | 16 | 3.8 | 7 | entrectinib 600 mg daily | 8.6 | false | MSS | 2026-03-15T05:36:01.888890+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_529746 | REC_0016787 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 28 | 6.5 | 70 | female | 1 | 5 | 7 | 6 | pembrolizumab 200 mg q3w | 8.8 | true | MSS | 2026-03-15T05:36:01.889353+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_618679 | REC_0016788 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 30 | 14.9 | 60 | female | 1 | 16 | 5.9 | 5 | osimertinib 80 mg daily | 14 | false | MSS | 2026-03-15T05:36:01.889781+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_977248 | REC_0016789 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 20 | 8.2 | 71 | female | 1 | 56 | 5.5 | 1 | carboplatin + paclitaxel + pembrolizumab | 17.4 | true | MSS | 2026-03-15T05:36:01.890194+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_532567 | REC_0016790 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 25 | 8.8 | 66 | female | 1 | 39 | 4.6 | 4 | carboplatin + paclitaxel + pembrolizumab | 15.7 | true | MSS | 2026-03-15T05:36:01.890602+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_885318 | REC_0016791 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 20 | 12.8 | 56 | male | 0 | 24 | 5.2 | 2 | alectinib 600 mg BID | 18 | false | MSI-H | 2026-03-15T05:36:01.891059+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_707962 | REC_0016792 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 28 | 12.3 | 65 | female | 1 | 21 | 6.8 | 2 | osimertinib 80 mg daily | 12.5 | false | MSS | 2026-03-15T05:36:01.891480+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_445362 | REC_0016793 | Non-small cell lung cancer | Squamous cell carcinoma | III | None | 24 | 8.4 | 73 | female | 1 | 22 | 7.9 | 0 | carboplatin + paclitaxel + pembrolizumab | 15.8 | false | MSS | 2026-03-15T05:36:01.891891+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_392298 | REC_0016794 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 27 | 8.2 | 74 | female | 2 | 34 | 6.8 | 4 | carboplatin + paclitaxel + pembrolizumab | 4.2 | true | MSS | 2026-03-15T05:36:01.892373+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_668492 | REC_0016795 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 18 | 10.7 | 69 | female | 0 | 3 | 5.3 | 7 | osimertinib 80 mg daily | 15.5 | false | MSI-H | 2026-03-15T05:36:01.892791+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_321158 | REC_0016796 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 24 | 11.1 | 56 | female | 0 | 21 | 6.2 | 1 | entrectinib 600 mg daily | 21.9 | false | MSS | 2026-03-15T05:36:01.893202+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_336103 | REC_0016797 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 23 | 12.6 | 74 | male | 1 | 10 | 3.9 | 2 | osimertinib 80 mg daily | 25.6 | false | MSI-H | 2026-03-15T05:36:01.893753+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_765581 | REC_0016798 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 21 | 11.8 | 66 | female | 1 | 9 | 4.2 | 6 | sotorasib 960 mg daily | 6.5 | true | MSS | 2026-03-15T05:36:01.894160+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_713825 | REC_0016799 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 28 | 11.6 | 73 | female | 0 | 6 | 4.5 | 5 | alectinib 600 mg BID | 16.3 | true | MSS | 2026-03-15T05:36:01.894555+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_254047 | REC_0016800 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 23 | 15.3 | 59 | male | 0 | 11 | 5.5 | 5 | osimertinib 80 mg daily | 16.9 | true | MSS | 2026-03-15T05:36:01.894960+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.